News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Icahn Raises Stake in Amylin Pharmaceuticals, Inc. to 7.3 Percent
September 15, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LOS ANGELES, Sept 12 (Reuters) - Billionaire investor Carl Icahn has raised his stake in biotechnology company Amylin Pharmaceuticals Inc to 7.33 percent, according to documents filed on Friday with the U.S. Securities and Exchange Commission.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Autoimmune disease
Sanofi Taps Dren Again in up to $1.7B Autoimmune Partnership
December 15, 2025
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
Sobi Makes $1.5B Gout Play With Arthrosi Acquisition
December 15, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Pfizer Is Not a Done Dealmaker After Metsera Buy, With $6B More To Spend
December 10, 2025
·
1 min read
·
Annalee Armstrong
Japan
Japanese Pharmas Looking Beyond Borders for M&A to US, EU
December 10, 2025
·
7 min read
·
Dan Samorodnitsky